FDA details kidney damage in Gilead’s Quad studies

With an FDA panel looming, agency staff raised concerns about the risk of kidney damage seen in studies of Gilead Sciences' ($GILD) HIV treatment Quad. The staff review comes days ahead of a panel of…
Read the full story: News